PMV Pharmaceuticals, Inc. (PMVP): restructuring charge — PMV Pharma cuts workforce 30%, extends cash runway to end of 2026

PMV Pharmaceuticals, Inc.

Workforce reduction of ~30% to prioritize PC14586 development and streamline operations.
Unaudited cash, cash equivalents, and marketable securities of ~$229M as of Dec 31, 2023.
Expected non-recurring charges of ~$1.4M for employee severance and benefits, mainly in Q1 2024.
Cash runway now expected to extend to end of 2026 due to cost savings.
Registrational Phase 2 trial for PC14586 remains on track to initiate in Q1 2024.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

PMV Pharmaceuticals, Inc. announced a restructuring with charges of approximately $1.4 million (approximately 30% of the Company’s employees).

Type: restructuring
Charge: approximately $1.4 million
Headcount: approximately 30% of the Company’s employees

Exact text from the filing

development for its lead product candidate, PC14586. As a result of the reduction in force, the Company expects to incur aggregate non-recurring charges of approximately $1.4 million, consisting primarily of employee severance and benefit costs associated with the restructuring. The Company expects that most of these charges will be cash expenditures and that

View on SEC.gov

Browse all restructurings & charges →

PMV Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-010177

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.